Drugs / ONVITRELIN UCALONTIDE
ONVITRELIN UCALONTIDE
also known as
EP-100 · EP-100 (PEPTIDE) · Onvitrelina ucalontida · Onvitreline ucalontide · Ucalolictide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00949559 | Jul 2009 → Mar 2012 | cancer | Esperance Pharmaceuticals Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01485848 Comparator | Feb 2012 → May 2014 | ovarian carcinoma | Esperance Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONVITRELIN UCALONTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297748 ↗ |
| Known as | EP-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00949559 ↗ |
| Known as | EP-100 (PEPTIDE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297748 ↗ |
| Known as | Onvitrelina ucalontida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297748 ↗ |
| Known as | Onvitreline ucalontide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297748 ↗ |
| Known as | Ucalolictide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297748 ↗ |
| Modality | Peptide | “Membrane-Disrupting Peptide” NCT01485848 ↗ |
| Route | Intravenous | “administered intravenously” NCT00949559 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor binding agent” CHEMBL4297748 ↗ |